Drugs / AGG-523
AGG-523
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT00427687 | Feb → Jun 2007 | osteoarthritis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00434785 | Feb → Sep 2007 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00369304 | Jul → Aug 2006 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00380900 | Jul 2006 → Feb 2007 | osteoarthritis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00454298 Comparator | May 2007 → Mar 2008 | osteoarthritis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGG-523 | “There will be 2 parallel cohorts of 12 subjects each who will be enrolled to receive single doses of tolbutamide or AGG-523 plus tolbutamide in periods 1 and 2 in a crossover design.” NCT00369304 ↗ |
| Known as | PF-05212371 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4859268 ↗ |
| Known as | PF-5212371 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4859268 ↗ |
| Known as | WAY-266523 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4859268 ↗ |
| Action | Inhibit | “an investigational aggrecanase inhibitor” NCT00454298 ↗ |
| Modality | Small molecule | — CHEMBL4859268 ↗ |
| Route | Oral | “Administered Orally” NCT00380900 ↗ |